Galapagos

8 trials 1 recruiting Commercial sponsor

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

1 Recruiting

5 Completed trials

13 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase I (FiH)

Phase III: 1 Phase II: 2 Phase I (Other): 3 Phase I (FiH): 2

Oversight events:

1 unexpected event across 1 trial

View oversight register →

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Systemic lupus erythematosus 2 Autoimmune disorder 1 Dermatomyositis 1

Top IMPs

BCMACP03 2 BCN-CP01 2 GLPG3667 FUMARATE 2 19CP02 1

All trials

8 total

Relative bioavailability and effect of food study with GLPG3667 in healthy subjects Pending

2026-525706-35-00 Phase I (Other) 1 country
Thorough QT/QTc study with GLPG3667, placebo, and active comparator in healthy subjects Pending

2026-525788-42-00 Phase I (Other) 1 country
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies Recruiting

2023-510173-34-00 Phase III 4 countries 19CP02; BCMACP03; BCN-CP01
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell… Ended

2022-500782-27-00 Phase I (FiH) 2 countries BCMACP03
A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended

2023-503183-16-00 Phase II 6 countries GLPG3667 FUMARATE
A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended

2022-501097-19-00 Phase II 10 countries GLPG3667 FUMARATE
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Ended

2022-501686-47-00 Phase I (FiH) 3 countries BCN-CP01
A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosu… Ended

2023-504422-19-00 Phase I (Other) 2 countries

Showing 1–8 of 8 trials

← All sponsors A–Z